Sarepta Therapeutics annual total debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Total Debt Growth & History (SRPT)
Sarepta Therapeutics's total debt was $1.04B for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.04B | −$303.3M | −22.59% |
| 2024 | 2024-12-31 | $1.34B | −$53.9M | −3.86% |
| 2023 | 2023-12-31 | $1.40B | −$220.6M | −13.64% |
| 2022 | 2022-12-31 | $1.62B | $997.1M | +160.77% |
| 2021 | 2021-12-31 | $620.2M | $518.9M | +512.29% |
| 2020 | 2020-12-31 | $101.3M | $45.7M | +82.30% |
| 2019 | 2019-12-31 | $55.6M | −$365.0M | −86.79% |
| 2018 | 2018-12-31 | $420.6M | −$10.5M | −2.44% |
| 2017 | 2017-12-31 | $431.1M | $413.4M | +2339.73% |
| 2016 | 2016-12-31 | $17.7M | −$9.2M | −34.17% |
| 2015 | 2015-12-31 | $26.8M | $25.3M | +1605.08% |
| 2014 | 2014-12-31 | $1.6M | −$94,000 | −5.64% |
| 2013 | 2013-12-31 | $1.7M | −$89,000 | −5.07% |
| 2012 | 2012-12-31 | $1.8M | −$85,000 | −4.61% |
| 2011 | 2011-12-31 | $1.8M | −$81,000 | −4.21% |
| 2010 | 2010-12-31 | $1.9M | — | — |
Sarepta Therapeutics quarterly total debt
Q4.10
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q4.15
Q4.16
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.05B | $831.4M | +387.76% |
| Q1 2026 | 2026-03-31 | $1.04B | $831.2M | +404.56% |
| Q4 2025 | 2025-12-31 | $1.04B | −$303.3M | −22.59% |
| Q3 2025 | 2025-09-30 | $355.5M | −$1.04B | −74.56% |
| Q2 2025 | 2025-06-30 | $214.4M | −$1.16B | −84.35% |
| Q1 2025 | 2025-03-31 | $205.5M | −$1.17B | −85.10% |
| Q4 2024 | 2024-12-31 | $1.34B | −$53.9M | −3.86% |
| Q3 2024 | 2024-09-30 | $1.40B | $26.1M | +1.90% |
| Q2 2024 | 2024-06-30 | $1.37B | $5.2M | +0.38% |
| Q1 2024 | 2024-03-31 | $1.38B | $91.1M | +7.07% |
| Q4 2023 | 2023-12-31 | $1.40B | −$220.6M | −13.64% |
| Q3 2023 | 2023-09-30 | $1.37B | −$206.5M | −13.09% |
| Q2 2023 | 2023-06-30 | $1.36B | $1.33B | +3366.49% |
| Q1 2023 | 2023-03-31 | $1.29B | $1.25B | +3235.62% |
| Q4 2022 | 2022-12-31 | $1.62B | $997.1M | +160.77% |
| Q3 2022 | 2022-09-30 | $1.58B | $1.51B | +2387.86% |
| Q2 2022 | 2022-06-30 | $39.4M | −$25.9M | −39.70% |
| Q1 2022 | 2022-03-31 | $38.6M | −$22.1M | −36.35% |
| Q4 2021 | 2021-12-31 | $620.2M | $518.9M | +512.29% |
| Q3 2021 | 2021-09-30 | $63.4M | −$4.8M | −7.04% |
| Q2 2021 | 2021-06-30 | $65.3M | −$7.1M | −9.83% |
| Q1 2021 | 2021-03-31 | $60.7M | −$4.6M | −7.03% |
| Q4 2020 | 2020-12-31 | $101.3M | $45.7M | +82.30% |
| Q3 2020 | 2020-09-30 | $68.2M | $10.9M | +19.00% |
| Q2 2020 | 2020-06-30 | $72.4M | $15.0M | +26.20% |
| Q1 2020 | 2020-03-31 | $65.3M | $6.3M | +10.75% |
| Q4 2019 | 2019-12-31 | $55.6M | −$365.0M | −86.79% |
| Q3 2019 | 2019-09-30 | $57.3M | −$358.1M | −86.20% |
| Q2 2019 | 2019-06-30 | $57.4M | −$382.1M | −86.94% |
| Q1 2019 | 2019-03-31 | $58.9M | −$371.9M | −86.32% |
| Q4 2018 | 2018-12-31 | $420.6M | −$10.5M | −2.44% |
| Q3 2018 | 2018-09-30 | $415.4M | $377.7M | +1000.78% |
| Q2 2018 | 2018-06-30 | $439.4M | — | — |
| Q1 2018 | 2018-03-31 | $430.8M | — | — |
| Q4 2017 | 2017-12-31 | $431.1M | $413.4M | +2339.73% |
| Q3 2017 | 2017-09-30 | $37.7M | — | — |
| Q4 2016 | 2016-12-31 | $17.7M | −$9.2M | −34.17% |
| Q4 2015 | 2015-12-31 | $26.8M | $25.3M | +1605.08% |
| Q1 2015 | 2015-03-31 | $1.5M | −$96,000 | −5.84% |
| Q4 2014 | 2014-12-31 | $1.6M | −$94,000 | −5.64% |
| Q3 2014 | 2014-09-30 | $1.6M | −$92,000 | −5.44% |
| Q2 2014 | 2014-06-30 | $1.6M | −$91,000 | −5.32% |
| Q1 2014 | 2014-03-31 | $1.6M | −$90,000 | −5.19% |
| Q4 2013 | 2013-12-31 | $1.7M | −$89,000 | −5.07% |
| Q3 2013 | 2013-09-30 | $1.7M | −$88,000 | −4.95% |
| Q2 2013 | 2013-06-30 | $1.7M | −$88,000 | −4.89% |
| Q1 2013 | 2013-03-31 | $1.7M | −$86,000 | −4.72% |
| Q4 2012 | 2012-12-31 | $1.8M | −$85,000 | −4.61% |
| Q3 2012 | 2012-09-30 | $1.8M | −$84,000 | −4.51% |
| Q2 2012 | 2012-06-30 | $1.8M | −$83,000 | −4.41% |
| Q1 2012 | 2012-03-31 | $1.8M | — | — |
| Q4 2011 | 2011-12-31 | $1.8M | −$81,000 | −4.21% |
| Q3 2011 | 2011-09-30 | $1.9M | — | — |
| Q2 2011 | 2011-06-30 | $1.9M | — | — |
| Q4 2010 | 2010-12-31 | $1.9M | — | — |
Sarepta Therapeutics total debt trends
Over the last five fiscal years, Sarepta Therapeutics's total debt increased from $101.3M to $1.04B, a change of $938.3M. The latest reported quarter, Q2 2026, shows $1.05B.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...